Angiotech Pharmaceuticals, Inc.
Vancouver, BC
Company Overview
ANGIOTECH PHARMACEUTICALS INC. Angiotech Pharmaceuticals (NASDAQ: ANPI; TSX: ANP) is a world leader in the emerging field of drug-coated medical devices and biomaterials. We are pioneering the science of adding drugs to medical devices and biomaterials to dramatically improve their performance and solve some of medicines most vexing problems.
The Companys rapid growth is attributable to the discovery that the antiproliferative drug, paclitaxel, could also block an important cellular pathway involved in inflammation. Angiotechs premier formulation of paclitaxel is a stent coating to prevent restenosis in coronary arteries. Coronary stent sales presently are US$2.3 billion annually, despite the fact that they fail in approximately 25 to 50 percent of cases within six months. The advent of the paclitaxel-eluting stent, which works over 600 percent better than the basic bare stent, has borne compelling economic arguments and analysts now predict that the industry will grow to US$5 billion or even as high as $14 billion annually.
Angiotech is ready to take the same strategy from its drug- eluting stent program to a whole new level to countless other medical device and biomaterials that are placed in the human body every year. These devices and biomaterials can be greatly enhanced through co-administration of a drug (such as paclitaxel) designed to improve the performance of the product. Major medical device companies are now beginning to recognize this technological shift. But Angiotech has been anticipating and preparing for this shift for the past ten years and has methodically built internal capabilities to lead the effort.
The Companys history began in 1992 with the efforts of its Co- Founder and current president and CEO, William Hunter, MD, MSc, to build the core technologies that serve as Angiotechs foundation. Weve since grown to become one of the largest pharmaceuticals companies in Canada, but well continually strive to redefine and improve therapies in novel and innovative ways to benefit patients worldwide.
Company Information
Physical Address
1618 Station St.
Vancouver, BC V6A 1B6
CA
Mailing Address
1618 Station St.
Vancouver, BC V6A 1B6
CA
Additional Details
Legal Name: Angiotech Pharmaceuticals, Inc.
Number of Employees: 132
Total Sales ($CDN): $100,000 - $200,000
CA
Contacts
Jeanne Bertonis
Title: Chief Business Officer
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
David Mcmasters
Title: VP, Intellectual Property & Corp Counsel
Phone: Show phone
Fax: Show fax
Email: Show email
Rui Avelar
Title: Vice President, Investor Relations
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
George Daniloff
Title: General Manager & VP, R&D
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Ross Erickson
Title: Vice President, Operations
Area of Responsibility: Manufacturing/Production/Operations
Phone: Show phone
Fax: Show fax
Email: Show email
William L. Hunter Md
Title: President and CEO
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
David Hall
Title: Chief Financial Officer
Area of Responsibility: Finance/Accounting
Phone: Show phone
Fax: Show fax
Email: Show email
Services
- Biotechnology
- Drug-loaded Biomaterials
Products
- Adhibit
- Coseal
- Costasis
-
Paclitaxel Films
Polymer films containg paclitaxel vascular graft Status: Preclinical testing
-
Paclitaxel Gels And Creams
Topical Gels and Creams containing paclitaxel Psoriasis Status: Phase I clinical testing
-
Paclitaxel Pastes
Paclitaxel Pastes
- Surgical adhesions
- Cancer
Status: Preclinical testing
- Paclitaxel Stent Coatings
-
Paxceed
Micellar Paclitaxel for Rheumatoid Arthritis and Severe Psoriasis
Additional Information
541690